Drug Profile
Interleukin-4 gene therapy
Latest Information Update: 15 Aug 2007
Price :
$50
*
At a glance
- Originator Chiron Corporation; Hopital Avicenne; McMaster University; Nonindustrial source
- Class Cytokine genes; Gene therapies; Interleukins
- Mechanism of Action Interleukin 4 stimulants; Macrophage stimulants; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 08 Apr 2003 No development reported - Preclinical for Cancer in Italy (unspecified route)
- 08 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 08 Apr 2003 No development reported - Preclinical for Inflammatory bowel disease in Canada (Parenteral)